Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III clinical study switching paroxysmal nocturnal hemoglobinuria (PNH) patients from eculizumab treatment to Coversin

Trial Profile

A Phase III clinical study switching paroxysmal nocturnal hemoglobinuria (PNH) patients from eculizumab treatment to Coversin

Recruiting
Phase of Trial: Phase III

Latest Information Update: 30 Sep 2018

At a glance

  • Drugs Nomacopan (Primary) ; Eculizumab
  • Indications Paroxysmal nocturnal haemoglobinuria
  • Focus Therapeutic Use
  • Acronyms ASSET
  • Most Recent Events

    • 30 Sep 2018 Status changed from planning to recruiting, according to an Akari Therapeutics media release.
    • 06 Feb 2018 According to an Akari media release, company plans to initiate this trial in the end of first quarter of 2018.
    • 08 Dec 2017 According to an Akari media release, company plans to initiate this trial in the second half of 2018 and will include Soliris switch patients.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top